Mazdutide
GLP-1 / metabolic · By Preptide Pro editorial team · Last updated
Mazdutide is a glp-1 / metabolic peptide, and it is not FDA-approved. An investigational dual GLP-1 and glucagon receptor agonist. In clinical trials for obesity and type 2 diabetes.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 167312357 |
|---|---|
| CAS number | 2259884-03-0 |
| Molecular formula | C207H317N45O65 |
| Molecular weight | 4476 g/mol |
| Other names | Mazdutide, IBI362, GTPL13924, IBI-362, GLXC-26803, compound 1 [US9938335B2], EX-A12490, LY3305677 |
Is Mazdutide FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Mazdutide?
PubMed lists 57 records for “mazdutide”, of which 10 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications. | J Diabetes Metab Disord | 2026 Dec |
| Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. | Lancet Diabetes Endocrinol | 2026 Nov |
| Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report. | J Clin Med | 2026 Oct 20 |
| The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease. | Diabetes Obes Metab | 2026 Oct 14 |
| The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus. | Obes Rev | 2026 Oct 11 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.